Medical device companies' aggregate spend on payment and other gifts to physicians was at least $200 million last year, according to the U.S. Health & Human Services Dept., but critics (and the agency itself) flag widespread problems with the Open Payments database.
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
A look at the top 10 politicial action committee donations shows that medtech is betting heavily on a GOP win in the midterm elections.
The medical device industry is betting on a Republican sweep of the U.S. Congress during the 2014 mid term elections, according to a MassDevice.com analysis of donations made by the industry's 10 largest political action committees.
The U.S. attorney for Massachusetts subpoenas Novo Nordisk for documents on its plant in Denmark that makes half the world's supply of insulin.
(Reuters) - Denmark's Novo Nordisk , the world's biggest maker of insulin, has received a U.S. subpoena requesting documents relating to potential manufacturing issues at its Kalundborg plant in Denmark, the company said on Friday.
Here's a look at some of the top legal news stories for medical device companies this week: Sinopsys Surgical sniffs up $8.3m for sinusitis device; ZipLine Medical adds $5.7m to Series C round; Medrobotics taps backers for $20m; Sensory Medical raises $1.4m for Relaxis restless legs treatment; Stealth hypertension startup Sympara Medical raises nearly $6m
EndoStim, which makes an implantable device to treat gastroesophageal reflux disease, reportedly tables its initial public offering due to poor market conditions.
EndoStim, citing poor market conditions, has tabled its initial public offering it hoped would raise nearly $36 million for its neurostimulation device for gastroesophageal reflux disease, according to Renaissance Capital.
EndoStim had planned to put $10 million of the IPO's proceeds into clinical studies and another $14 million to commercialize the system.